Program
lumacaftor
Also written as “LUM/IVA”, “Lumacaftor” and “VX-809”.
Its studies are mostly in Cystic Fibrosis · Cognitive Dysfunction, led by 3 companies.
Drug pageLumacaftor: every studyAll 24 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticalsits history only | 210 open or running | phase 4since Aug 15, 2016 | Mar 18, 2009 | none ahead |
| Qanatpharma | 11 open or running | phase 2since May 5, 2025 | May 5, 2025 | May 2027phase 2 · NCT07695090 |
| Qanatpharma Canadaits history only | 10 open or running | phase 1since Jul 21, 2023 | Jul 21, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Qanatpharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 5, 2025First study: phase 2 study in Cognitive DysfunctionFirst studyNCT07695090 · 60 planned · Canada
Ahead
- May 2027Primary completion: phase 2 study in Cognitive DysfunctionNCT07695090
TargetBeta
“Cystic fibrosis transmembrane conductance regulator stabiliser”ChEMBL 37, by rule
Other programs on CFTR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivacaftorrule | Vertex Pharmaceuticals | phase 4 | 78 |
| tezacaftorrule | Vertex Pharmaceuticals | phase 3 | 39 |
Studies
The one study Qanatpharma leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07695090Cognitive Dysfunction · Canada | 2 | Recruiting | May 2027 | 60 |
How it is read
Names in the registry
- “LUM/IVA”, 8 entries
- “Lumacaftor”, 5 entries
- “VX-809”, 4 entries
- “Lumacaftor Plus Ivacaftor Combination”, 3 entries
- “Lumacaftor 200 MG”, 1 entry
Conditions, from the studies’ own filings
- Cystic Fibrosis, 20 studies
- Cognitive Dysfunction, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.